Dashboard
Manage Tickers

KLRS Allovir, Inc.

Nasdaq allovir.com


$ 5.37 $ 0.13 (2.44 %)    

Friday, 14-Nov-2025 15:54:47 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 609.18 $ 0.00 (0 %)
DIA $ 471.61 $ 0.00 (0 %)
SPY $ 671.97 $ 0.00 (0 %)
TLT $ 89.26 $ 0.00 (0 %)
GLD $ 375.00 $ 0.00 (0 %)
$ 5.46
$ 5.10
$ 5.00 x 2
$ 5.59 x 60
-- - --
$ 2.14 - $ 15.63
48,448
na
102.12M
$ 1.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-07-2025 01-01-1970 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-15-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-15-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-10-2022 12-31-2021 10-K
17 11-05-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 02-12-2021 12-31-2020 10-K
21 11-10-2020 09-30-2020 10-Q
22 09-02-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
11/12/2025 21:05:55

Core News & Articles
Kalaris Therapeutics Q3 EPS $(0.64) Beats ...
11/12/2025 13:14:02

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of ...

Core News & Articles
Citizens Initiates Coverage On Kalaris The...
11/03/2025 14:05:51

Citizens analyst Jonathan Wolleben initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform rating ...

Core News & Articles
Kalaris Therapeutics Appoints Matthew Gall...
11/03/2025 12:38:36

Kalaris Therapeutics ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercia...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
10/06/2025 17:07:04

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/02/2025 17:06:31

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/16/2025 17:07:35

Core News & Articles
Kalaris Therapeutics Now Enrolling Phase 1...
09/15/2025 12:09:25

Core News & Articles
12 Health Care Stocks Moving In Friday's A...
09/12/2025 21:06:30

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 12:08:12

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/03/2025 21:06:23

Core News & Articles
Raymond James Initiates Coverage On Kalari...
09/03/2025 16:47:52

Raymond James analyst Chris Raymond initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Strong Buy rating and an...

Core News & Articles
Kalaris Therapeutics Shares Resume Trade F...
09/03/2025 15:20:57

Core News & Articles
Kalaris Therapeutics Shares Resume Trade
09/03/2025 15:01:42

Core News & Articles
Kalaris Therapeutics Shares Halted On Circ...
09/03/2025 15:00:17

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/28/2025 21:06:27

why-snowflake-shares-are-trading-higher-by-14-here-are-20-stocks-moving-premarket
Why Snowflake Shares Are Trading Higher By...
08/28/2025 09:48:22

Core News & Articles
Kalaris Therapeutics Q2 EPS $(0.61) Misses...
08/13/2025 12:06:29

Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate o...

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
06/09/2025 12:08:42

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/04/2025 12:08:36

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION